Effect of hyaluronidase on mortality and morbidity in patients with early peaking of plasma creatine kinase MB and non-transmural ischaemia: Multicentre investigation for the limitation of infarct size (MILIS)

Robert Roberts, Eugene Braunwald, James E. Muller, Charles Croft, Herman K. Gold, Tyler D. Hartwell, Allan S. Jaffe, Suzanne M. Mullin, Corette Parker, Eugene R. Passamani, W. Kenneth Poole, Thomas Robertson, Daniel S. Raabe, Robert E. Rude, Peter H. Stone, Zoltan G. Turi, Burton E. Sobel, James T. Willerson

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

A multicentred, randomised, blind study was started in 1978 to compare propranolol or hyaluronidase with placebo in patients with acute myocardial infarction admitted within 18 hours of onset of symptoms. Patients were randomised to group A and received hyaluronidase, propanolol, or placebo, or, if propranolol was contraindicated, to group B and received hyaluronidase or placebo. Hyaluronidase (500 U/kg given every six hours for 48 hours) had no effect on mortality or infarct size in the overall population. Because spontaneous reperfusion was more common in patients with early peaking of plasma creatine kinase MB or non-transmural electrocardiographic changes or both, the results were reanalysed for two subgroups: those in whom plasma creatine kinase peaked < 15 hours after the onset of symptoms (early peak, n = 184) and those with a peak > 15 h after the onset of symptoms (late peak, n = 546). The distribution of time to peak activity of creatine kinase MB was similar in the hyaluronidase and placebo groups. In the early peak patients who were given hyaluronidase (groups A and B) total mortality and cardiacspecific four year mortality were significantly lower. This was most pronounced in group B in which the total mortality was 45% and cardiovascular mortality was 47% less than in the placebo group. Similarly, mortality from cardiovascular disease in patients (groups A and B) with non-transmural ischaemia (ST-T changes) given hyaluronidase was significantly lower, with group B showing a 50% reduction. In the subsets of patients with late peaking of creatine kinase MB or those presenting with transmural electrocardiographic changes there was no difference in total mortality or deaths from cardiac disease between those given hyaluronidase and those given placebo. Hyaluronidase was associated with improved survival in patients with early peaking of plasma creatine kinase MB, suggesting the possibility of salvage of myocardium in patients who have early spontaneous reperfusion and possibly after therapeutic reperfusion.

Original languageEnglish (US)
Pages (from-to)290-298
Number of pages9
JournalHeart
Volume60
Issue number4
DOIs
StatePublished - Jan 1 1988

    Fingerprint

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Roberts, R., Braunwald, E., Muller, J. E., Croft, C., Gold, H. K., Hartwell, T. D., Jaffe, A. S., Mullin, S. M., Parker, C., Passamani, E. R., Poole, W. K., Robertson, T., Raabe, D. S., Rude, R. E., Stone, P. H., Turi, Z. G., Sobel, B. E., & Willerson, J. T. (1988). Effect of hyaluronidase on mortality and morbidity in patients with early peaking of plasma creatine kinase MB and non-transmural ischaemia: Multicentre investigation for the limitation of infarct size (MILIS). Heart, 60(4), 290-298. https://doi.org/10.1136/hrt.60.4.290